ERBB2 and breast cancer: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for approximately 15–20% of all breast cancers, and its prognosis has been improved in the past two decades by new treatments such as trastuzumab, pertuzumab and lapatinib (Loibl and Gianni, 2017).